| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2001;72:1144-1148
© 2001 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA
Address reprint requests to Dr D’Amico, Division of Cardiothoracic Surgery, Duke University Medical Center, Box 3496, Durham, NC 27710
e-mail: damic001{at}mc.duke.edu
Presented at the Thirty-seventh Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 29–31, 2001.
Background. The use of molecular markers in staging non-small cell lung cancer (NSCLC) has been supported in retrospective prognostic models but has not been evaluated in predicting sites of metastases.
Methods. Pathologic specimens were collected from 202 patients after complete resection for stage I NSCLC, who were subsequently found to have no metastases at 5 years (n = 108), isolated brain metastases (n = 25), or other distant metastases (n = 69). A panel of eight molecular markers of metastatic potential was chosen for immunohistochemical analysis of the tumor: p53, erbB2, angiogenesis factor viii, EphA2, E-cadherin, urokinase plasminogen activator (UPA), UPA receptor, and plasminogen activator inhibitor.
Results. Patients with isolated brain relapse had significantly higher expression of p53 (p = 0.02) and UPA (p = 0.002). The quantitative expression of E-cadherin was used to predict the site of metastases using recursive partitioning: 0 of 92 patients with E-cadherin expression of 0, 1, or 2 developed isolated cerebral metastases; 0 of 33 patients with E-cadherin expression of 3 with UPA of 1 or 2 and ErbB2 of 0 developed brain metastases. Of the remaining patients at risk (UPA = 3), the risk of isolated cerebral metastases was 21 of 57 patients (37%).
Conclusions. This study demonstrates that molecular markers may predict the site of relapse in early stage NSCLC. If validated in an ongoing prospective study, these results could be used to select patients with isolated brain metastases for adjuvant therapy, such as prophylactic cranial irradiation.
This article has been cited by other articles:
|
|
 |
|
  J.-W. Lee, H. D. Han, M. M. K. Shahzad, S. W. Kim, L. S. Mangala, A. M. Nick, C. Lu, R. R. Langley, R. Schmandt, H.-S. Kim, et al. EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma J Natl Cancer Inst, September 2, 2009; 101(17): 1193 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Grinberg-Rashi, E. Ofek, M. Perelman, J. Skarda, P. Yaron, M. Hajduch, J. Jacob-Hirsch, N. Amariglio, M. Krupsky, D. A. Simansky, et al. The Expression of Three Genes in Primary Non-Small Cell Lung Cancer Is Associated with Metastatic Spread to the Brain Clin. Cancer Res., March 1, 2009; 15(5): 1755 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Wesa, C. J. Herrem, M. Mandic, J. L. Taylor, C. Vasquez, M. Kawabe, T. Tatsumi, M. S. Leibowitz, J. H. Finke, R. M. Bukowski, et al. Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists J. Immunol., December 1, 2008; 181(11): 7721 - 7727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mujoomdar, J. H. M. Austin, R. Malhotra, C. A. Powell, G. D. N. Pearson, M. C. Shiau, and H. Raftopoulos Clinical Predictors of Metastatic Disease to the Brain from Non-Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases Radiology, March 1, 2007; 242(3): 882 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer. J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lindegaard, P. Isager, J. U. Prause, and S. Heegaard Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3268 - 3275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Gaspar, K. Chansky, K. S. Albain, E. Vallieres, V. Rusch, J. J. Crowley, R. B. Livingston, and D. R. Gandara Time From Treatment to Subsequent Diagnosis of Brain Metastases in Stage III Non-Small-Cell Lung Cancer: A Retrospective Review by the Southwest Oncology Group J. Clin. Oncol., May 1, 2005; 23(13): 2955 - 2961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Herrem, T. Tatsumi, K. S. Olson, K. Shirai, J. H. Finke, R. M. Bukowski, M. Zhou, A. L. Richmond, I. Derweesh, M. S. Kinch, et al. Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 226 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hu, K. L. Carles-Kinch, D. P. Zelinski, and M. S. Kinch EphA2 Induction of Fibronectin Creates a Permissive Microenvironment for Malignant Cells Mol. Cancer Res., October 1, 2004; 2(10): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iwasaki, T. Shirakusa, Y. Yoshinaga, S. Enatsu, and M. Yamamoto Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 488 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DiPerna, R. D. Bart, E. M. Sievers, Y. Ma, V. A. Starnes, and R. M. Bremner Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1129 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Marchevsky, J.-H. Qiao, S. Krajisnik, J. M. Mirocha, and R. J. McKenna The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tatsumi, C. J. Herrem, W. C. Olson, J. H. Finke, R. M. Bukowski, M. S. Kinch, E. Ranieri, and W. J. Storkus Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma Cancer Res., August 1, 2003; 63(15): 4481 - 4489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cobos, C. Jumper, and C. Lox Pretreatment Determination of the Serum Urokinase Plasminogen Activator and its Soluble Receptor in Advanced Small-Cell Lung Cancer or Non-Small-Cell Lung Cancer Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 241 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Walker-Daniels, A. R. Hess, M. J.C. Hendrix, and M. S. Kinch Differential Regulation of EphA2 in Normal and Malignant Cells Am. J. Pathol., April 1, 2003; 162(4): 1037 - 1042. [Full Text] [PDF]
|
|
|
|
|
|
I. Milas, R. Komaki, T. Hachiya, R. S. Bubb, J. Y. Ro, L. Langford, R. Sawaya, J. B. Putnam, P. Allen, J. D. Cox, et al. Epidermal Growth Factor Receptor, Cyclooxygenase-2, and BAX Expression in the Primary Non-Small Cell Lung Cancer and Brain Metastases Clin. Cancer Res., March 1, 2003; 9(3): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kinch, M.-B. Moore, and D. H. Harpole Jr. Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival Clin. Cancer Res., February 1, 2003; 9(2): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Smythe Treatment of Stage I Non-small Cell Lung Carcinoma Chest, January 1, 2003; 123 (2009): 181S - 187S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
